The predictive value of cell-of-origin subtype in patients with DLBCL receiving polatuzumab vedotin

Edward Cliff, MPH, MBBS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia, discusses a retrospective multi-center observational study on the use of polatuzumab vedotin in patients with diffuse large B-cell lymphoma (DLBCL). Dr Cliff highlights that patients with non-GCB-type DLBCL had better responses than those with GCB-type DLBCL when they were categorized using Hans algorithm immunohistochemistry. This study encourages clinicians to consider cell-of-origin by Hans algorithm when deciding whether to use polatuzumab. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.